Antimicrobial Resistance Diagnostics Markets: Strategies and Trends by Pathogen and Technology with Executive Guides and Customization 2022 - 2026
“Will diagnostics solve the problem? Multiple diagnostic technologies create new global race.”
Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have identified the 6 key large pathogen opportunities in this space and developed market forecasts out to 2025. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens and infections can be diagnosed. We profile more than 30 companies, large and small, working in this area.
Forecasts are provided to 2026 and are broken out by country, pathogen and five different technology opportunities; microbiology culture, immunoassay, PCR, next-generation sequencing (NGS), mass spectrometry and rapid POC. Additional breakout data relevant to your own areas of interest is available upon request, and free of charge with the corporate license.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
Make investment decisions and market valuations with confidence using the latest data.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School